Abstract:Introduction Type 2 diabetic nephropathy (T2DN) is the leading cause of end-stage renal disease (ESRD) in the U.S., with a particularly high prevalence among Black/African Americans (B/AAs). B/AAs experience higher rates of type 2 diabetes (T2D) incidence, accelerated nephropathy progression (< 20 years), and ESRD compared to European Americans (EAs). While significant strides have been made in understanding the combined effects on T2DN risk, research on T2DN and T2D-ESRD resilience remains limited. Resilience focuses on identifying protective factors in individuals who maintain normal kidney function despite high T2D risk. Methods Leak et al. (2009) were the first to comprehensively investigate and identify intron 8 SNPs (rs1345365, rs2058730, rs10951509, and rs1981740) significantly associated with reduced risk (OR = 0.77-0.84) of T2D-ESRD in a B/AA discovery cohort, replication cohort, and combined case-control cohort (1,136 controls and 1,160 cases) after adjusting for genetic admixture. We extended these analyses in an independent population of 15,195 EA and 3,195 B/AA normoglycemia T2D controls and 9,124 T2DN cases (EA: N=3,185 and B/AA: N=5,939) in the All of Us Research Program (AoURP), the largest dataset of individual-level phenotypic, social, and genetic data, and in B/AA participants from 23andMe, a personal genomics company (Controls: N=18,075; T2DN: N=17,331; T2D-ESRD: N=1,568). Results In the AoURP, single-SNP genotypic association analyses adjusted for age at T2D diagnosis, sex at birth, and BMI confirmed the association with the SNPs (OR = 0.71-0.83; P-values ranging from 0.02 to 0.03). Interestingly, these SNPs are associated with T2DN risk in EA (OR ranging from 1.04 to 1.32). In 23andMe, using 3,944 imputed SNPs spanning introns 8 through 15, single-SNP genotypic association results adjusted for age, sex, and genome-wide principal components (1-6) revealed that the most significant genotypic associations were novel intron 8 rare SNPs associated with T2D-ESRD (P-value = 2.08 × 10 -4 ) and T2DN (P-values ranging from 1.68 × 10 -4 to 2.83 × 10 -4 ) risk. The relationship between rs1345365, rs1981740, rs10951509, and rs2058730 showed protective effects (OR = 0.79-0.89) for T2D-ESRD, consistent with previous findings. Interestingly, the minor allele frequencies (MAF) of the replicated and the novel rare SNPs more closely resemble the MAF of West Africans. Conclusion These findings suggest that the resilience relationship between T2DN and T2D-ESRD in B/AAs with intron 8 SNPs may be the result from the complex interplay of gene-gene, gene-social determinants of health (SDoH), and/or genetic admixture interactions. Hence, these findings warrant further genotypic association analyses of ∼17,000 SNPs spanning this 78.2kb enhancer-rich region. Additionally, using the AoURP, we seek to understand why some individuals experience longer duration from T2D diagnosis to DN onset (≥20 years) or avoid developing DN despite experiencing adverse SDoH and being at relatively high genetic risk. Understanding these factors bridges the gap between disease-driven genetic analysis and personalized healthcare, ultimately improving therapeutic strategies.

Polygenic Risk for Type 2 Diabetes in African Americans

Development and validation of a trans-ancestry polygenic risk score for type 2 diabetes in diverse populations

Polygenic Prediction of Type 2 Diabetes in Africa

Meta-Analysis of Genome-Wide Association Studies in African Americans Provides Insights into the Genetic Architecture of Type 2 Diabetes

Variant level heritability estimates of type 2 diabetes in African Americans

Evaluation of polygenic risk scores to differentiate between type 1 and type 2 diabetes

Type 1 Diabetes Risk in African-Ancestry Participants and Utility of an Ancestry-Specific Genetic Risk Score

A comparison of type 2 diabetes risk allele load between African Americans and European Americans

Genome-Wide Polygenic Risk Score Predicts Incident Type 2 Diabetes in Women With History of Gestational Diabetes

An Improved Genome-Wide Polygenic Score Model for Predicting the Risk of Type 2 Diabetes

Insights on the pathogenesis of type 2 diabetes as revealed by signature genomic classifiers in an African American population in the Washington, DC area

Abstract A021: Development of cross-ancestry polygenic risk. scores for breast cancer in women of African ancestry

Multi-ancestry polygenic mechanisms of type 2 diabetes

The clinical relevance of a polygenic risk score for type 2 diabetes mellitus in the Korean population

Integrated clinical risk prediction of type 2 diabetes with a multifactorial polygenic risk score

Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis

139-OR: Large-Scale Sex-Stratified Additive and Recessive GWAS Identifies Novel Large-Effect Variants and Improves Polygenic Prediction for Type 2 Diabetes

Type 2 Diabetes Partitioned Polygenic Scores Associate With Disease Outcomes in 454,193 Individuals Across 13 Cohorts

Evaluating the use of blood pressure polygenic risk scores across race/ethnic background groups

Beyond Risk: Exploring Genetic Determinants of T2DN Resilience in the All of Us Research Program